dev@fecani.se 
Vironova Medical AB (publ), 559008-5303 invite shareholders to the Extraordinary General Meeting on the 25th of May 2023. The meeting will be held at Convendum, Gävlegatan 16 at 14:00. We need your registration by the 19th of May. You register via regular mail, so be sure to send your registration for the postal services to … Read more
Vironova Medical AB (publ), 559008-5303 invite shareholders to the Annual General Meeting on the 17th of November 2022. The meeting will be held at Vironova Medical AB´s premises, Gävlegatan 22, floor 8, at 14:00. We need your registration by the 11th of November. You register via regular mail, so be sure to send your registration … Read more
Vid årsstämman i Vironova Medical AB (publ) den 30 juni 2021 fattades följande beslut Stämman genomfördes enligt 20 och 22 §§ lagen (2020:198) om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor, innebärande att aktieägarna fått utöva sin rösträtt vid stämman endast genom att rösta på förhand, s.k. poströstning. Fastställande av årsbokslut och … Read more
Vironova Medical AB (publ), 559008-5303 invites shareholders to the Annual General Meeting at the 30th of June 2021. The meeting will take place online only. We need your registration for the meeting by the 29th of June. You register via regular mail, so be sure to send your registration for the postal services to get … Read more
Vironova Medical AB are developing a novel class of antiviral drugs against covid-19/SARS-CoV-2, first evaluated in vitro against SARS-CoV-2 virus at the University of Melbourne in Australia in March 2020. The results showed good inhibition of the virus. Two independent international laboratories, The National Institute of Health (NIH) in the US and Commonwealth Scientific and … Read more
The shareholders of Vironova Medical AB (publ), 559008-5303, are hereby invited to the Annual General Meeting at 14:00 on the 30th of June 2019 at Vironova Medical’s premises, Gävlegatan 22, 113 30 Stockholm. To register please visit: https://www.vironova.com/registration-for-annual-meeting-2020-in-vironova-medical-ab
Vironova Medical will be at the ISIRV conference Options X for the control of Influenza Singapore 28 August-1 September https://2019.isirv.org
Meet us in Ghent on the 17th-20th of June for the XVIII International Conference on Heterocycles in Bioorganic chemisty. Vironova Medical is the main sponsor of the event. Our Senior Scientist and Chemist Ngarita Kingi will give an oral presentation with the title: Thionations Using a P4S10-Pyridine Complex.
Vironova Medical was invited to participate in the renowned Swedish American Life Science Summit SALSS, an annual meeting that brings together scientists, entrepreneurs and investors with the aim is to build strategic and collaborative relationships between academia, industry and fundings.
STOCKHOLM, SWEDEN – Vironova AB (publ), a leading Nano-Characterization technology and software company, announced the approval of a new US-patent application. The patent cover topical administration against herpes with B-220 compound in U.S. (US2013310392). “Problems with resistance and reactivation of the dormant infection need to be approached by implementing new innovations and providing alternative drug … Read more
Finance and Accounting Manager
Konsult från Almarekonmi byrå. Tigare anställd på Vironova AB
Principal Scientist
Ph.D. in Organic Chemistry from the Zelinsky Institute of Organic Chemistry (Russian Acad. Science). M.Sc. in Chemistry from The Moscow State University. Employed at Vironova Medical AB since 2020. Previously at Uppsala Universitet, Novadex AB and Medivir AB.
Marketing Director
Chief of Communication at Vironova AB. He has been in management roles and worked as a management consultant providing consultative advice and services in strategy development with focus towards digital strategy and transformation framework, demand and lead generation management, sales and marketing strategy. Working with C-level and middle management with change initiatives to bridge the gap between strategy and execution. Mats holds a M.Sc. in Financial Economics from Gothenburg University. Previously CMO and Management Consultant at ProSales Institute and ProSales Consulting.
Investor Relations
Text coming soon…
CEO
Ph.D. in Medicine from the Karolinska Institute. M.Sc. in Biotechnology from The Royal Institute of Technology. Employed at Vironova AB and Vironova Medical AB since 2014. Previously CSO at Vironova Medical AB.
Board Member
M.Sc., Stockholm School Economics, MBA University of California, Berkeley
20+ years of experience in board positions, currently board member at Prolight Diagnostics, Newfour, QBNK. Previously CEO at several Swedish companies including AGA Gas, Thermiaverken and Candor.
Suppleant
Ph.D. in Polymer Technology from The Royal Institute of Technology. Previous manager at Akzo Nobel. AB. Board member in Vironova AB.
Board Member
M.Sc., Stockholm School of Economics. Board Member in RISE, N-side, Leuwen Belgium, and Nobelux. Industrial adviser at EQT. 25 years of experience in the pharmaceutical industry, most recently 10 years as President Europe in Astra Zeneca, based in Brussels.
Board Member
Professor in anesthesiology and intensive care since 1999 at the Department of Clinical Science, Intervention and Technology at Karolinska Institute. Commercial pharmaceutical “Adenosine” in the U.S. market through licensing with Astellas Pharma.
Co-founder and Chairman
M.Sc. In Chemistry and B.Sc. in Biology from Uppsala University. Founder and Chairman of the board in Vironova AB and founder of Vironova Medical AB.